AYTU BIOPHARMA INC (AYTU) Stock Balance Sheet
NASDAQ:AYTU - Nasdaq - US0547548588 - Common Stock - Currency: USD
| MRQ (2024-12-31) | 2024 (2024-6-30) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 20.40M | 20.01M | 23.00M | 19.40M | 49.60M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Receivables | 25.40M | 23.62M | 28.90M | 21.70M | 28.20M | |||
| Inventories | 11.09M | 12.63M | 12.00M | 10.80M | 16.30M | |||
| Other Current Assets | 6.17M | 5.63M | 8.90M | 8.00M | 11.10M | |||
| Total Current Assets | 63.05M | 61.89M | 72.80M | 59.90M | 105.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.69M | 1.52M | 3.90M | 6.30M | 8.70M | |||
| Goodwill | N/A | N/A | N/A | 0.00 | 65.80M | |||
| Intangibles | 49.96M | 52.45M | 59.00M | 70.60M | 85.50M | |||
| Other Non-Current Assets | 1.52M | 2.23M | 800.00K | 800.00K | 500.00K | |||
| Total Non-Current Assets | 53.17M | 56.20M | 63.70M | 77.70M | 160.50M | |||
| TOTAL ASSETS | 116.23M | 118.09M | 136.50M | 137.60M | 265.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 4.01M | 2.40M | 1.60M | 3.80M | 7.90M | |||
| Current Portion Of LT Debt. | 1.86M | 1.86M | 100.00K | 100.00K | 16.70M | |||
| Accrued Expenses | 32.53M | 29.32M | 37.00M | 35.90M | 49.50M | |||
| Accounts Payable | 18.72M | 20.40M | 24.50M | 20.50M | 28.00M | |||
| Other Current Liabilities | 6.93M | 8.25M | 5.80M | 4.10M | 7.40M | |||
| Total Current Liabilities | 64.05M | 62.23M | 69.00M | 64.40M | 109.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 9.98M | 10.88M | 14.70M | 14.30M | 200.00K | |||
| Other Non-Current Liabilities | 11.43M | 17.27M | 13.40M | 12.80M | 18.50M | |||
| Total Non-Current Liabilities | 21.41M | 28.15M | 28.10M | 27.10M | 18.70M | |||
| TOTAL LIABILITIES | 85.46M | 90.38M | 97.10M | 91.50M | 128.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -317.71M | -319.97M | -304.10M | -288.50M | -178.30M | |||
| Additional Paid In Capital | 348.48M | 347.69M | 343.50M | 334.60M | 315.90M | |||
| Common Shares | 1.00K | 1.00K | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 6.17M | 5.97M | 5.50M | 1.90M | 1.40M | |||
| Tangible Book Value per Share | -3.11 | -4.14 | -3.56 | -12.89 | -9.79 | |||
| Total Shareholders' Equity | 30.77M | 27.72M | 39.40M | 46.10M | 137.60M | |||
| TOTAL LIABILITIES AND EQUITY | 116.23M | 118.09M | 136.50M | 137.60M | 265.70M | |||
| Statistics | ||||||||
| Debt/Equity | 0.45 | 0.48 | 0.41 | 0.39 | 0.06 | |||
| Current Ratio | 0.98 | 0.99 | 1.06 | 0.93 | 0.96 | |||
| Return On Assets (ROA) | -4.51% | -13.42% | -12.53% | -79.07% | -21.94% | |||
| Return On Equity (ROE) | -17.04% | -57.17% | -43.40% | -236.01% | -42.37% | |||
All data in USD , ROIC based on taxRate of 0.21